Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hepatitis C × Sorafenib × Clear all

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 70 Carcinoma, Renal Cell 33 Neoplasms 31 Liver Neoplasms 20 Carcinoma 6 Thyroid Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Kidney Neoplasms 3 Breast Neoplasms 3 Vaccinia 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Lymphoma 1 Liver Diseases 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Insulin-Like Growth Factor I, Resistance To 1 Hypophosphatemia 1 Hepatitis C 1 Hepatitis B 1 Glioblastoma 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Carcinoma, Medullary 1

Interventions

menatetrenone 1 ledipasvir, sofosbuvir drug combination 1 hepatitis C immune globulin, human 1 Sorafenib 1 Sofosbuvir 1 Ribavirin 1 Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04710641 2025-03-06

OUTREACH2

Mina Alpha Limited

Phase 2 Completed

Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡